John Spinale

John Spinale is a Co-Founder and Managing Partner of JAZZ Venture Partners, a San Francisco–based venture firm focused on "human performance" — technologies at the convergence of technology, science, and humanity that improve how people live, learn, work, and play. He brings more than two decades of experience as an operator, entrepreneur, and investor in consumer media and technology, and earned a degree in engineering from Yale.

Before JAZZ, Spinale held senior operating roles across consumer and enterprise technology companies. He was general manager of Disney Interactive's mobile and social games division, where he led a turnaround and launched multiple chart-topping titles. He was also an early executive at OnLive, the pioneering cloud/interactive streaming games and media platform later acquired by Sony. Earlier in his career he was involved in the restructuring and relaunch of Activision in the 1990s before moving into startups, and he co-founded NileGuide (acquired by Travora).

In his role at JAZZ, Spinale sits on the boards of several portfolio companies, including Outside, Form Bio, and Sounding Board. The firm manages roughly $287M in assets across its funds and invests across enterprise, wellness, healthcare, and consumer markets.

• Invests in "transformative technologies that unlock human potential" — JAZZ's stated aim is to "partner with founders creating companies that measurably improve human health, performance, productivity, and wellbeing."
• Firm-level mission: backing "breakthroughs at the convergence of technology, science, and humanity — improving how we live, work, and experience the world."
• Stage: seed through Series B (early and growth stage).
• Check size: $100K–$5.0M, sweet spot around $1.5M.
• Core sectors: digital health and digital therapeutics, wellness/health optimization, neuroscience and brain-computer interfaces, AI, and consumer technology/media — Spinale personally leans on his consumer-tech, gaming, and media background.
• Looks for science- or evidence-backed approaches to human performance (the firm's portfolio is heavy on clinically/scientifically validated products).